Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5

Background: In the onset 5 trial, fast-acting insulin aspart (faster aspart) was noninferior to insulin aspart (IAsp) for change from baseline glycated hemoglobin at 16 weeks, when used in continuous subcutaneous insulin infusion by participants with type 1 diabetes. The aim of this post hoc analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorst-Rasmussen, Anders, Sturis, Jeppe, Ekelund, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783624/
https://www.ncbi.nlm.nih.gov/pubmed/34524005
http://dx.doi.org/10.1089/dia.2021.0199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783624/
https://www.ncbi.nlm.nih.gov/pubmed/34524005
http://dx.doi.org/10.1089/dia.2021.0199

Ejemplares similares